Wegovy oral tablet supports near-term growth, but patent and pipeline risks weigh on long-term valuation

Overview

Novo Nordisk reported strong second-quarter 2026 results and raised full-year guidance, but the share price still fell by about 4% after the results release. Market focus has shifted from near-term earnings beats to R&D pipeline competitiveness and the risk of long-term semaglutide exclusivity expiry. Goldman Sachs believes the early commercial performance of Wegovy oral tablets in the United Kingdom and the United Arab Emirates is the main current highlight and raises near-term operating forecasts; however, the ZEUS and REIMAGINE-4 trial results have weakened long-term growth expectations, so it maintains a Neutral rating and lowers the target price.

Core views

In the near term, Wegovy oral tablets are expected to become a potentially underestimated growth driver by removing injection barriers, attracting patients who have not previously used GLP-1, and expanding overseas markets. Over the medium to long term, semaglutide exclusivity expiry in some markets, successive pipeline setbacks, and the lack of visible growth sources sufficient to replace the core obesity business will continue to weigh on valuation. Investors will demand that management clarify the business development and M&A framework at the Capital Markets Day, but the market remains skeptical about Novo Nordisk's past performance in integrating large acquisitions and bolt-on assets.

Analysis framework

The report updates the 2026–2030 earnings model by combining second-quarter results and conference-call information, investor communications, product-level sales forecasts, adjustments to clinical project probabilities of success, and company guidance; on valuation, it uses a combination of bottom-up discounted cash flow analysis and relative valuation, and tests target-price risks through scenarios for product ramp-up, patent expiry, R&D failure, competition, and pricing.

Methodology notes

• Earnings forecastProduct-level bottom-up forecast

  Update revenue and profit forecasts by product, indication, and region

  Raised forecasts for Wegovy oral tablets in the United States and overseas, removed ziltivekimab sales, and lowered peak sales forecasts for CagriSema in diabetes and obesity; as a result, 2026–2030 revenue was raised by about 2% on average and operating profit by about 3%.

• Pipeline valuationRisk-adjusted probability-of-success method

  Adjust R&D project probabilities of success and expected sales based on clinical results

  After the failure of the Phase 3 ZEUS trial, the probability of success for ziltivekimab was reduced from 40% to 0%; the REIMAGINE-4 data led to a further reduction in CagriSema-related forecasts.

• Absolute valuationDiscounted cash flow valuation (DCF)

  Discount future cash flows to present value

  Using a 7% weighted average cost of capital and a -2% perpetual growth rate, the valuation is DKK278 per share, below the previous DKK309.

• Relative valuationP/E valuation

  Estimate equity value based on 2027 earnings per share and a reasonable P/E multiple

  The reasonable P/E multiple was lowered from 14.5x to 13x to reflect the negative impact of the ZEUS and REIMAGINE-4 failures on long-term growth, corresponding to a valuation of DKK289 per share.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Novo Nordisk (NOVOb.CO)

  The Danish-listed stock primarily covered by the report

  Strengths

  Second-quarter results beat expectations, full-year guidance was raised, Wegovy oral tablets launched strongly in the United Kingdom and the United Arab Emirates, and the global GLP-1 market still has structural growth potential.

  Weaknesses

  The obesity business is highly concentrated, recent R&D success has been insufficient, and long-term growth is becoming increasingly dependent on pipeline supplementation and business development.

  Comparison

  The report believes that after adjustments, the company's 2027 core earnings P/E is about 10.5x, representing about a 20% discount to the roughly 13.5x average for large European pharmaceutical companies; however, investors also compare it with Sanofi, which faces major patent expiries and an insufficient pipeline.

  Risks

  Semaglutide exclusivity expiry, CagriSema or amycretin R&D failure, capacity expansion falling short of expectations, stronger data from competing products, and continued pricing pressure.

• Novo Nordisk ADR (NVO)

  The American depositary receipt corresponding to the Danish-listed stock

  Strengths

  Shares the fundamental opportunities brought by the commercialization of Wegovy oral tablets and the expansion of the global GLP-1 market.

  Weaknesses

  Long-term pipeline uncertainty and exclusivity-expiry risk are consistent with the Danish-listed stock, with additional impact from exchange-rate translation.

  Comparison

  The ADR target price refers to the Danish-listed stock and is translated at the current exchange rate, with a target price of $44 and a current price of $44.53.

  Risks

  In addition to company fundamentals risks, it also includes the impact of changes in the Danish krone/U.S. dollar exchange rate on ADR valuation and returns.

Key data

• Underlying revenue in the second quarter of 2026Exceeded expectations by 5%The company also raised guidance for fiscal 2026.
• Underlying operating profit in the second quarter of 2026Exceeded expectations by 15%The company raised the midpoint of both revenue and operating profit guidance by 5 percentage points.
• Quarterly variance for Wegovy oral tabletsBelow market expectations by about DKK50 million/$7 millionThe shortfall was small, but some investors had previously expected channel stocking to drive higher revenue.
• United Kingdom launch of Wegovy oral tabletsAbout 300,000 patients in the first three weeks after launchNovo Nordisk's share of the obesity GLP-1 market rose from about 30% to about 45%.
• Comparable patient scale in the United StatesAbout 80,000 to 90,000 patientsThe early launch pace in the United Kingdom was clearly faster, but may include one-off concentrated demand.
• Oral obesity market share in the United Arab EmiratesAbout 50%Wegovy oral tablets were launched after competing products, but still quickly achieved a high share.
• 2026–2030 forecast adjustmentsRevenue about +2%; operating profit about +3%The increase in Wegovy oral tablet forecasts offset part of the impact from the removal of ziltivekimab and the reduction in CagriSema.
• CagriSema diabetes peak sales forecastDKK5.5 billionThe previous forecast was DKK13.9 billion.
• CagriSema and cagrilintide obesity peak sales forecastDKK16.1 billionThe previous forecast was DKK19.8 billion.
• Discounted cash flow valuationDKK278/sharePreviously DKK309/share.
• Relative valuationDKK289/shareBased on a 13x P/E multiple on forecast 2027 earnings per share.
• 12-month target priceDKK285/sharePreviously DKK310/share; implies 3.2% downside versus the current price listed in the report.

Impact & implications

Strong results and the ramp-up of Wegovy oral tablets can improve near-term earnings delivery, but are not yet sufficient to change market concerns about the long-term growth gap. If the rapid launch in the United Kingdom can be partially replicated in other overseas markets such as Germany, there is still room for earnings forecasts to be raised; conversely, if the impact of exclusivity expiry in Canada and Brazil, pricing pressure, and intensifying competition exceed expectations, Novo Nordisk may face further earnings and valuation downgrades. Whether management can establish the next round of growth drivers through successful internal R&D or high-quality bolt-on M&A will be key to medium- to long-term re-rating.

Risks

• Sales growth of Wegovy oral tablets is below expectations, and early overseas ramp-up may include unsustainable one-off concentrated demand.
• Subsequent clinical development of CagriSema or amycretin fails, further weakening the long-term competitiveness of the obesity product portfolio.
• Manufacturing capacity expansion for Wegovy and Ozempic is slower than expected, limiting product supply and sales delivery.
• Competitors' obesity data are better than expected, especially for oral small-molecule GLP-1 assets.
• The impact of semaglutide exclusivity expiry in Canada, Brazil, and other markets exceeds expectations.
• Drug pricing pressure deepens and lasts longer, eroding revenue, margins, and terminal value.
• Business development or M&A fails to identify suitable assets, or post-acquisition integration and clinical performance are poor.
• Upside risks include faster-than-expected ramp-up of Wegovy oral tablets and CagriSema peak sales above current forecasts.

What to watch

• The September 21, 2026 Capital Markets Day's explanation of strategic priorities, acquisition direction, and asset-screening criteria.
• Patient retention, refill prescriptions, and sustainability of early ramp-up for Wegovy oral tablets in the United Kingdom and the United Arab Emirates.
• The pace of market expansion after Wegovy oral tablets are scheduled to enter Germany in September 2026.
• Patient eligibility reviews, prior authorization, reimbursement progress, and the prescription mix between injectable and oral formulations under the U.S. Medicare Part D Bridge program.
• The actual revenue and pricing impact of semaglutide exclusivity expiry in Canada and Brazil in the second half of 2026.
• The balance in 2027 between structural growth in the GLP-1 market, launch contributions from CagriSema and Mim8, and headwinds from exclusivity expiry.
• Phase 3 SYNCHRONY real-world data for efruxifermin, though this data is not the dataset used for regulatory filing.
• Whether subsequent internal R&D outcomes and bolt-on M&A can reduce concentration in the obesity business.